What is InMode's Q2 2026 revenue guidance?

InMode has guided Q2 2026 revenue to $95.2–$95.4 million, which sits above consensus expectations and reflects mid-to-high single-digit growth. This guidance signals continued strong demand for the company's RF, laser, and energy-device portfolio across geographies.

What is InMode's full-year 2026 revenue target?

InMode has reiterated full-year 2026 guidance of $365–$375 million, representing mid-to-high single-digit growth. This range implies sequential growth in Q3–Q4, likely driven by seasonal demand for skin-tightening and resurfacing procedures in the Northern Hemisphere fall and winter.

How is the Steel Partners acquisition affecting InMode's business outlook?

The pending Steel Partners takeover creates uncertainty around long-term roadmap visibility and pricing strategy, though InMode's steady guidance demonstrates operational resilience. Practice owners should monitor the August 5 earnings call for commentary on competitive positioning and international expansion, as these areas could shift under new ownership.

Why is InMode's Q2 guidance significant for med spa owners?

The Q2 beat above consensus expectations indicates device revenue is holding strong despite macro uncertainty and acquisition clouds. This suggests continued market demand for RF, laser, and energy-based treatments, providing confidence for practices planning capital equipment investments.

When should med spa owners expect seasonal demand peaks for InMode devices?

InMode's Q3–Q4 guidance implies seasonal demand peaks in the Northern Hemisphere fall and winter months, driven by increased patient interest in skin-tightening and resurfacing procedures. Practice owners should plan inventory and marketing accordingly for these higher-demand periods.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Business & M&A

InMode Guides Q2 2026 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M Full-Year Target

InMode's Q2 beat and full-year guidance hold steady despite acquisition uncertainty.

By Evan at Inside MedSpa · Jul 17, 2026

1-YEAR MOVE

INMD ▲1.0%

1-year price move by ticker
Ticker	Company	1-year change
INMD	InMode Ltd.	+1.0%

InMode has guided Q2 2026 revenue to $95.2–$95.4 million and reiterated full-year 2026 guidance of $365–$375 million, representing mid-to-high single-digit growth. The Q2 guidance sits above consensus expectations, suggesting continued demand for the company's RF, laser, and energy-device portfolio across geographies.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/inmode-q2-2026-revenue-guidance-95-2-95-4-million/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

InMode Guides Q2 2026 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M Full-Year Target

Share

Discussion

Leave a comment

By the time it's news, it's too late.